SalaryGuide
AboutPricingFor Employers

Marketing jobs

1 marketing jobs

Hims & Hers logo
3 weeks ago

Director, Product & Marketing Analytics

Hims & Hers

USA (Remote)Full time$210K/yr – $260K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

1 jobs
Hims & Hers logo

Director, Product & Marketing Analytics

Hims & Hers

USA (Remote)

$210K/yr - $260K/yrIn-houseFull-timeDirector/executive12+ years exp.
3 weeks ago
Hims & Hers logo
Hims & Hers

Director, Product & Marketing Analytics

USA (Remote)

$210K/yr – $260K/yrDirector/Executive12+ years expFull time

Posted 3 weeks ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own retention analytics and causal-inference work for a subscription business, turning data into actionable CRM, product, and marketing interventions.

  • Retention analytics and experimentation: cohort design, churn decomposition, and ROI-focused interventions across the subscription lifecycle.
  • Executive storytelling and stakeholder alignment: translate complex findings for GMs, VPs, and C-suite to guide roadmaps and investments.
  • MTI/MMM and segmentation: drive multi-touch incrementality, cross-channel mix, and audience prioritization with quarterly finance targets.

Job Description

  • Serve as the analytics thought partner to GMs, VPs of Product, and Marketing leadership, shaping roadmaps and investment decisions through data
  • Represent analytics in cross-functional forums, translating technical findings into executive-ready narratives and influencing decisions at the C-suite level
  • Maintain visibility into macro-level business sensitivities: e.g., how a 2.5pp shift in retention translates to quarterly and annual revenue impact
  • Own retention analytics across the subscription lifecycle, including cohort design, churn window decomposition, and segment-level intervention prioritization (product type, WL prior experience, check-in engagement, dose adjustment)
  • Define hero metrics, guardrail metrics, and dashboard frameworks to monitor performance across membership and Rx subscription populations in real time
  • Design experimental and observational analyses to identify causal drivers of retention and churn, and translate findings into CRM, product, and clinical interventions
  • Partner with product and clinical teams on evaluation of new features and treatment protocols, side-effect management, check-in experience, snooze/save mechanics
  • Guide segmentation strategy across user attributes to prioritize where retention investment has the highest ROI
  • Lead the transition from MTA to MTI (Multi-Touch Incrementality), including MMM validation, incrementality test design (geo holdouts, go-dark tests), cross-category halo methodology, and calibration aligned to quarterly finance targets
  • Partner with Marketing leadership to assess paid channel efficiency across SEM, Social, OTT TV, Podcast, and emerging channels, with a clear view of where MTI and MTA diverge and why
Hims & Hers logo

Hims & Hers

Hims & Hers Health, Inc. (better known as Hims & Hers) is a multi-specialty telehealth platform building a virtual front door to the healthcare system. We connect consumers to licensed healthcare professionals, enabling people to access high-quality medical care—from wherever is most convenient—for numerous conditions related to sexual health, hair care, mental health, skincare, primary care, and more. With products and services available across all 50 states and Washington, D.C., Hims & Hers is on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. We normalize health & wellness challenges—and innovate on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so we provide access to personalized care designed for results. At our core, our mission is deeply personal—because we too are customers. In January 2021, the company was listed on the NYSE and is traded under the ticker symbol “HIMS”. To learn more about our brand and offerings, you can visit hims.com and forhers.com.

Founded in 2017
San Francisco, California, USA
1.9K employees (209 in marketing)
bit.ly/4blaSl2

Traffic Signals

Monthly Visitors
525.9M
Monthly Google Ads Budget
$8.1K
Traffic Source Mix
Search
16.8%
Direct
59.4%
Referral
12.1%
Social
11.1%
Paid
0.6%

Headcount Trend

Current headcount: ~1.9K

Marketing Team

Marketing Team Size
147 (8% of company)
Median Career Experience
12 years
Median Tenure
3.2 years
Marketing Roles Posted (Last 30 Days)
4

People

HR / Recruitment

Jessica Dickerson
Jessica Dickerson
Senior Recruiter, Marketing
At the company for 3 years 9 months

Marketing Leadership

Alison McCoy
Alison McCoy
Vice President Brand Marketing
At the company for 1 year 5 months
Josh Groth
Josh Groth
VP Growth Marketing
At the company for 1 year 11 months
Hannah Schaefer
Hannah Schaefer
SVP, Integrated Marketing
At the company for 6 years 11 months
Nicholas Butson-Wedewer
Nicholas Butson-Wedewer
VP Growth Marketing
At the company for 3 years 7 months

Funding

Total Funding
$1.2B
Last Raise
$1B
Post IPO Debt, 10 months ago

Funding History

  • May 2025
    Post IPO Debt • $1B
  • Jan 2021
    Post IPO Equity • $75M
  • Mar 2020
    Private Equity

Recent News

Why Hims & Hers moved into lab testing
Nov 25, 2025 • Healthcare Brew
From Hair Loss To GLP-1: Hims & Hers Health Is Quietly Building A 2030 Healthcare Platform
Nov 25, 2025 • Seeking Alpha
Hims & Hers Expands Care Scope as Digital Health Platforms Evolve
Nov 25, 2025 • Yahoo Finance
Hims & Hers Health (HIMS) Launches $250 Million Buyback Amid Stock Slide
Nov 25, 2025 • Somos Hermanos -
Alignment Healthcare, Hims & Hers Health, Surgery Partners, Guardant Health, and Pediatrix Medical Group Stocks Trade Up, What You Need To Know
Nov 24, 2025 • TradingView
Why Hims & Hers Health Shares Are Rising
Nov 24, 2025 • TipRanks
Hims & Hers: The Growth Story Is Outside GLP-1s
Nov 24, 2025 • Seeking Alpha
Hims & Hers Accelerates Its Clinician-Led, Platform-Driven Care Model
Nov 21, 2025 • Yahoo Finance
Hims & Hers Health Options Trading: A Deep Dive into Market Sentiment
Nov 21, 2025 • Benzinga
A Fresh Look at Hims & Hers Health (HIMS) Valuation After Recent Share Price Volatility
Nov 20, 2025 • simplywall.st
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
Nov 19, 2025 • MSN
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
Nov 19, 2025 • MarketBeat
Hims & Hers Enters Blood Testing Amid Preventive Health Surge
Nov 19, 2025 • Athletech News
Hims & Hers (HIMS) Investors Keep the Faith as Stock Slides 15%
Nov 18, 2025 • TipRanks
Hims & Hers Enters DTC Diagnostics
Nov 18, 2025 • Fitt Insider
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
Nov 18, 2025 • Yahoo Finance
Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy
Nov 17, 2025 • Business Wire
Hims & Hers Health effects new up to $250M stock buyback program, shares up ~2% (HIMS:NYSE)
Nov 17, 2025 • Seeking Alpha
Hims & Hers names ex-FDA official Deb Autor as first policy chief
Nov 17, 2025 • Reuters
Hims & Hers Health, Inc. Announces $250 Million Share Repurchase Program Authorization
Nov 17, 2025 • Hims Investor Relations
Hims & Hers Launches ‘Labs’ to Expand Into Data-Driven Diagnostics
Nov 17, 2025 • Global Cosmetics News
Hims & Hers Health’s Valuation in Focus After Wrongful Death Lawsuit Raises New Questions
Nov 16, 2025 • Yahoo Finance
Hims launches lab testing for preventive care
Nov 13, 2025 • Endpoints News
Hims & Hers Introduces Labs, a Holistic, In-Depth Testing Experience That Puts Customers in Control of Their Health and Wellness Journeys
Nov 13, 2025 • Yahoo Finance
Family of WSU student who died by suicide in 2023 sues Hims & Hers Health, Theta Chi fraternity for wrongful death
Nov 13, 2025 • KREM
Hims & Hers Bets on Lab Testing to Boost Growth
Nov 13, 2025 • The Wall Street Journal
Hims & Hers Scales Technology-Enabled, Vertically Integrated Care
Nov 11, 2025 • Yahoo Finance
Hims & Hers: Fast-Fashion Healthcare Is The Future (Rating Upgrade) (NYSE:HIMS)
Nov 10, 2025 • Seeking Alpha
Why Hims & Hers Health (HIMS) Is Down 7.6% After Narrowing 2025 Revenue Guidance and Q3 Results
Nov 10, 2025 • Yahoo Finance
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?
Nov 9, 2025 • The Motley Fool
Hims & Hers Expands AI-Driven Personalized and Subscription-Based Care
Nov 7, 2025 • Nasdaq
Hims & Hers Health (HIMS) Looks to Turn GLP-1 Hype Into Health Empire
Nov 5, 2025 • TipRanks
Hims & Hers: GLP-1 Partnership Could Unlock Value (NYSE:HIMS)
Nov 5, 2025 • Seeking Alpha
Hims Reverses Lower Despite Potential Deal With Novo
Nov 4, 2025 • Investor's Business Daily
Hims & Hers gains as analysts welcome talks with Novo for Wegovy sales
Nov 4, 2025 • Seeking Alpha
Hims & Hers Health Stock (HIMS) Opinions on Menopause Care Launch
Nov 3, 2025 • Quiver Quantitative
Hims & Hers Health Third-Quarter Revenue Jumps as Subscribers Grow
Nov 3, 2025 • The Wall Street Journal
Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results
Nov 3, 2025 • Hims Investor Relations
Hims and Hers beats revenue estimates on strong subscriber growth
Nov 3, 2025 • Yahoo Finance
Hims & Hers in talks to offer Novo’s new obesity pill
Nov 3, 2025 • Modern Healthcare
Hims & Hers in talks with Novo Nordisk to sell Wegovy injections, new obesity pill
Nov 3, 2025 • Fierce Healthcare
Hims and Hers tops revenue estimates as telehealth provider attracts more users
Nov 3, 2025 • Reuters
Hims & Hers Health (HIMS): Exploring Valuation as Q3 Earnings and GLP-1 Launch Boost Market Activity
Nov 2, 2025 • Yahoo Finance
Hims & Hers Health (HIMS) Q3 Earnings: What To Expect
Nov 1, 2025 • TradingView
Hims & Hers Q3 Preview: Growth Faces a Confidence Test
Oct 31, 2025 • Yahoo Finance
Hims & Hers rises after JPMorgan ups position
Oct 31, 2025 • Sherwood News
Can Sustained Product Demand Drive HIMS Stock Before Q3 Earnings?
Oct 29, 2025 • Yahoo Finance
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Oct 27, 2025 • Yahoo Finance
Is Hims & Hers Health Still a Smart Opportunity After 124% Stock Surge in 2025?
Oct 25, 2025 • Yahoo Finance
Hims & Hers: Use This Drop Before It's Too Late (NYSE:HIMS)
Oct 25, 2025 • Seeking Alpha
Hims & Hers Short Interest Nears All-Time High, Buy The Dip?
Oct 24, 2025 • MarketBeat
Menopause Care Expansion Could Be a Game Changer for Hims & Hers Health (HIMS)
Oct 24, 2025 • simplywall.st
Moderately bullish activity in Hims and Hers Health with shares up 2.95%
Oct 24, 2025 • TipRanks
Hims & Hers: There's Opportunity In This Crash (Upgrade)
Oct 23, 2025 • Seeking Alpha
Hims & Hers Health, Inc. (HIMS): A Bull Case Theory
Oct 23, 2025 • Yahoo Finance
Should You Rethink Hims After Volatile Moves and New Product Launches in 2025?
Oct 22, 2025 • simplywall.st
Hims & Hers Advances AI-Powered Personalized Digital Healthcare
Oct 22, 2025 • Zacks Investment Research
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today
Oct 22, 2025 • Yahoo Finance
Hims & Hers rated Sector Weight at KeyBanc on margin worries
Oct 21, 2025 • Seeking Alpha
HIMS Stock Declines Despite Launch of New Specialty in Women's Health
Oct 21, 2025 • Zacks Investment Research
Hims & Hers Q3 Preview: Key Metrics I Want To See For Beating 2030 Guidance (HIMS)
Oct 21, 2025 • Seeking Alpha
HIMS Stock Declines Despite Launch of New Specialty in Women's Health
Oct 21, 2025 • Yahoo Finance
Hims & Hers: Q3 Could Provide Volatility, But The Long-Term Vision Remains Bright
Oct 21, 2025 • Seeking Alpha
Hims & Hers Health (HIMS) Stock Is Up, What You Need To Know
Oct 20, 2025 • Yahoo Finance
Hims & Hers Health: Roller Coaster Gift (NYSE:HIMS)
Oct 20, 2025 • Seeking Alpha
Hims & Hers Health (HIMS): Exploring Valuation Following Major Menopause Treatment Launch
Oct 19, 2025 • simplywall.st
Hims & Hers Health (HIMS): How the Menopause Launch Shapes Valuation and Growth Expectations
Oct 18, 2025 • Yahoo Finance
Hims & Hers Health down 11% after CEO Dudum stock sale disclosure
Oct 17, 2025 • Seeking Alpha
Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today
Oct 16, 2025 • Yahoo Finance
Hims & Hers Stock Jumps 9% After Huge Announcement
Oct 16, 2025 • Nasdaq
Hims & Hers: Ramping Up A New Billion-Dollar Segment (Rating Upgrade) (NYSE:HIMS)
Oct 16, 2025 • Seeking Alpha
Hims & Hers to Offer Treatments for Menopause, Perimenopause
Oct 15, 2025 • The Wall Street Journal
Hims & Hers Health enters menopause market in $1B revenue push
Oct 15, 2025 • FirstWord Pharma
Hims & Hers: Why I’m Betting On HIMS Heading To $100 (NYSE:HIMS)
Oct 13, 2025 • Seeking Alpha
Hims & Hers to Announce Third Quarter 2025 Financial Results on November 3, 2025
Oct 13, 2025 • Hims Investor Relations
Taking Advantage Of Hims & Hers Stock Volatility
Oct 10, 2025 • Investor's Business Daily
Why Hims & Hers Health (HIMS) Stock Is Nosediving
Oct 10, 2025 • Yahoo Finance
Customers Say Care Through Hims & Hers Matches, or Beats, the Doctor’s Office
Oct 9, 2025 • Business Wire
Hims Stock, Up 138%: IBD Stock Of The Day Makes Another Breakout Run
Oct 8, 2025 • Investor's Business Daily
Hims & Hers Looks To Close $10 ARPU Gap With Product Expansion And Partnerships
Oct 8, 2025 • Seeking Alpha
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Oct 7, 2025 • Yahoo Finance
Why Hims & Hers Stock Slipped Today
Oct 3, 2025 • The Motley Fool
Evaluating Hims & Hers Health (HIMS) Valuation After 39% Share Price Surge in the Past Month
Oct 3, 2025 • Yahoo Finance
$HIMS stock is down 8% today. Here's what we see in our data.
Oct 3, 2025 • Quiver Quantitative
Hims & Hers Health names new COO
Oct 2, 2025 • Seeking Alpha
Buy HIMS Stock At $56?
Oct 1, 2025 • Forbes
Hims & Hers Health, Inc. (HIMS) Laps the Stock Market: Here's Why
Sep 29, 2025 • Yahoo Finance
U.S. FDA sends drug advertising warning letters to Lilly, Novo, Hims
Sep 16, 2025 • Reuters
Why The FDA — And Investors — Just Slammed Hims Stock
Sep 16, 2025 • Investor's Business Daily
Hims & Hers Health (HIMS) Stock Trades Down, Here Is Why
Sep 16, 2025 • Yahoo Finance
Hims & Hers Health (HIMS): Buy, Sell, or Hold Post Q2 Earnings?
Sep 15, 2025 • Yahoo Finance
US FDA chief says Hims & Hers Super Bowl ad violated drug promotion rules
Sep 13, 2025 • Reuters
Hims & Hers Surges 64.1% in 6 Months: How to Play the Stock?
Sep 12, 2025 • Yahoo Finance
FDA Chief Says Hims’ Weight-Loss Drug Ad Breached Agency’s Rules
Sep 12, 2025 • Bloomberg Law News
Targeting Hims & Hers, F.D.A. Takes on a New Type of Drug Advertiser
Sep 12, 2025 • The New York Times
Hims & Hers Health expands into testosterone therapy after Novo Nordisk breakup
Sep 10, 2025 • FirstWord Pharma
Hims & Hers Health Expands Testosterone Offerings - WSJ
Sep 10, 2025 • The Wall Street Journal
Hims Launches New Category in Men’s Health with Exclusive Branded Oral Testosterone and Expanded Personalized Treatments
Sep 10, 2025 • Hims Investor Relations
Hims to Launch New Offerings for Men With Low Testosterone
Sep 10, 2025 • Bloomberg.com
Hims & Hers launches treatment plans for low testosterone
Sep 10, 2025 • Reuters